What is the recommended taper and symptomatic treatment for kratom withdrawal in an adult without serious medical conditions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Kratom Withdrawal Management

For kratom withdrawal in adults without serious medical conditions, initiate symptomatic treatment with clonidine (or tizanidine if hypotension is a concern), gabapentin, and hydroxyzine for 3-7 days, with buprenorphine/naloxone reserved for severe cases or failed symptomatic management, starting at 4/1 mg to 8/2 mg daily for those using <20g kratom/day or 12/3 mg to 16/4 mg daily for those using >40g/day.

Clinical Approach Algorithm

Step 1: Assess Severity and Kratom Use Pattern

  • Quantify daily kratom intake (grams per day) and duration of use
  • Screen for synthetic derivatives: Ask specifically about 7-hydroxymitragynine tablets or mitragynine pseudoindoxyl (MP), which cause more severe, rapid-onset withdrawal than traditional powdered kratom 1
  • Assess withdrawal severity: Look for opioid-like symptoms including myalgia, joint pain, lacrimation, rhinorrhea, yawning, insomnia, diarrhea, chills, tremors, anxiety, restlessness, and irritability 2
  • Check vital signs: Hypertension, tachycardia, and diaphoresis indicate more severe withdrawal 1

Step 2: First-Line Symptomatic Management (Most Cases)

Start with non-opioid medications for 72-96 hours 3, 1:

  • Clonidine: Directly attenuates opioid withdrawal symptoms but requires careful titration due to orthostasis/hypotension risk. Use symptom-triggered dosing 4, 3
  • Alternative: Tizanidine if hypotension is a concern (less effective but safer blood pressure profile) 4
  • Gabapentin: Mitigates anxiety, insomnia, and irritability 4, 1
  • Hydroxyzine: Scheduled dosing for anxiety and restlessness 3, 1
  • Loperamide: For gastrointestinal symptoms (avoid high doses due to arrhythmia risk) 4
  • Antiemetics: As needed for nausea 1
  • Trazodone or mirtazapine: For persistent insomnia 4

This approach successfully resolved symptoms in documented cases within 72-96 hours 1.

Step 3: Buprenorphine/Naloxone for Severe or Refractory Cases

Consider buprenorphine/naloxone when:

  • Symptomatic management fails after 3-4 days
  • Severe withdrawal symptoms (Clinical Opiate Withdrawal Scale >20)
  • High-dose kratom use (>40g/day)
  • Use of synthetic derivatives (7-hydroxymitragynine, MP)
  • Patient has failed multiple withdrawal attempts 5, 6

Dosing based on kratom consumption 6:

  • <20g kratom/day: Start 4/1 mg to 8/2 mg buprenorphine/naloxone daily
  • >40g kratom/day: Start 12/3 mg to 16/4 mg buprenorphine/naloxone daily
  • Strong correlation (0.84) exists between kratom dose and required buprenorphine dose 6

Taper strategy: After stabilization, taper using extended-release buprenorphine (100mg monthly injections × 2 months) or gradual sublingual taper over several weeks 5. The goal is durability over rapidity 4.

Step 4: Post-Acute Management

Naltrexone for relapse prevention: Once opioid-free interval is established (typically after buprenorphine taper completion), initiate naltrexone including extended-release injectable formulation. Notably, naltrexone does not precipitate withdrawal after kratom cessation, unlike with traditional opioids 1.

Critical Nuances

Synthetic Derivatives Require Different Approach

Mitragynine pseudoindoxyl (MP) acts as a highly potent μ-opioid receptor agonist with δ-opioid receptor antagonism, producing severe, rapid-onset withdrawal distinct from traditional kratom 1. These cases may require more aggressive symptomatic management or earlier buprenorphine initiation.

Buprenorphine vs. Methadone

While buprenorphine is the most studied option 5, 6, 2, recent evidence shows methadone in opioid treatment programs is well-tolerated and effective (93% retention), starting at 15-30mg with titration to mean maximum of 98.6mg 7. However, methadone requires specialized settings and DEA-registered programs, making buprenorphine more practical for most outpatient settings.

Common Pitfalls to Avoid

  • Don't assume standard urine toxicology will detect kratom: Specialized testing is required 1
  • Don't overlook polysubstance use: Frequently co-occurs and complicates management 8
  • Don't use high-dose loperamide: Can cause dangerous arrhythmias 4
  • Don't convert to methadone for outpatient weaning without special justification and experience, especially with high-dose users 4

Duration and Monitoring

Traditional kratom withdrawal is typically mild and delayed compared to classic opioids 1, but synthetic derivatives cause more severe symptoms. Most cases resolve with 3-7 days of symptomatic treatment 3, 1. If using buprenorphine, maintenance may extend several weeks to months before tapering 5, 6.

The evidence base for kratom withdrawal remains limited to case reports and small case series 6, 9, 3, but the approach mirrors established opioid withdrawal management principles adapted to kratom's unique pharmacology 4, 2.

References

3
Research

A Case Report of Kratom Addiction and Withdrawal.

WMJ : official publication of the State Medical Society of Wisconsin, 2016

9
Research

Kratom Withdrawal: A Systematic Review with Case Series.

Journal of psychoactive drugs, 2019

Related Questions

What is the recommended treatment protocol for an adult experiencing kratom withdrawal, including medication choices for mild to moderate and severe symptoms?
How should kratom withdrawal be managed in an adult patient who has stopped regular use and presents with anxiety, irritability, insomnia, myalgia, nausea, vomiting, diarrhea, and diaphoresis?
In a 33-year-old male on extended-release buprenorphine/naloxone (Brixadi) who is actively using alcohol and kratom (mitragynine 20 ng/mL) and has labs showing glucose 132 mg/dL, BUN 7.8 mg/dL, chloride 97 mmol/L, CO₂ 31 mmol/L, total protein 8.4 g/dL, albumin 5.6 g/dL, cotinine 1609 ng/mL, buprenorphine 121 ng/mL, norbuprenorphine 182 ng/mL, ETG >12500 ng/mL, ETS >5000 ng/mL, sertraline >2500 ng/mL, what is the appropriate management?
How long do withdrawal symptoms from kratom (Mitragyna speciosa) typically last?
What are the recommendations for buprenorphine‑naloxone (Suboxone) treatment of kratom withdrawal?
Is percutaneous coronary intervention (PCI) beneficial in a patient who suffered cardiac arrest and is currently comatose with a Glasgow Coma Scale of 3?
What are the types and benefits of external skin sutures placed on the nasal tip after rhinoplasty?
How should phosphate be replaced in a patient with a serum phosphate level of 1.5 mg/dL?
Does tapering the dose of mirtazapine increase the risk of suicidal ideation?
Is gadolinium contrast required for MRI evaluation of osteomyelitis?
What is the recommended next step in management for a patient with an enlarging fluorodeoxyglucose (FDG)‑avid multilobulated subpleural right upper lobe pulmonary nodule now measuring 19 × 18 mm with SUVmax 7.7, while other small pulmonary nodules are stable and non‑FDG‑avid?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.